INOCARDIA_LIMITED - Accounts


Company Registration No. 08573417 (England and Wales)
INOCARDIA LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2019
PAGES FOR FILING WITH REGISTRAR
INOCARDIA LIMITED
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 5
INOCARDIA LIMITED
BALANCE SHEET
AS AT
30 SEPTEMBER 2019
30 September 2019
- 1 -
2019
2018
Notes
£
£
£
£
Current assets
Debtors
4
160,877
142,350
Cash at bank and in hand
40,615
122,360
201,492
264,710
Creditors: amounts falling due within one year
5
(135,036)
(164,000)
Net current assets
66,456
100,710
Capital and reserves
Called up share capital
6
109
109
Share premium account
529,856
529,856
Profit and loss reserves
(463,509)
(429,255)
Total equity
66,456
100,710

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 30 September 2019 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the board of directors and authorised for issue on 31 March 2020 and are signed on its behalf by:
Dr J P Billson
Director
Company Registration No. 08573417
INOCARDIA LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2019
- 2 -
1
Accounting policies
Company information

Inocardia Limited is a private company limited by shares incorporated in England and Wales. The registered office is The Technocentre, Coventry University Technology Park, Puma Way, Coventry, West Midlands, CV1 2TT.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Revenue from contracts for the provision of professional services is recognised by reference to the stage of completion when the stage of completion, costs incurred and costs to complete can be estimated reliably. The stage of completion is calculated by comparing costs incurred, mainly in relation to contractual hourly staff rates and materials, as a proportion of total costs. Where the outcome cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that it is probable will be recovered.

1.3
Research and development expenditure

Research and development expenditure is written off against profits in the year in which it is incurred.

1.4
Cash at bank and in hand

Cash at bank and in hand are basic financial assets and include cash in hand and bank only.

1.5
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include corporation tax recoverable, other debtors and cash and bank balances, are initially measured at transaction price are subsequently carried at amortised cost less impairment. Financial assets classified as receivable within one year are not amortised.

INOCARDIA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2019
1
Accounting policies
(Continued)
- 3 -
Basic financial liabilities

Basic financial liabilities, including trade creditors, other creditors and other taxation and social security are initially recognised at transaction price and subsequently carried at amortised cost.

1.6
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.7
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

1.8
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.9
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.

INOCARDIA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2019
1
Accounting policies
(Continued)
- 4 -
1.10
Government grants

Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received.

 

A grant that specifies performance conditions is recognised in income when the performance conditions are met. Where a grant does not specify performance conditions it is recognised in income when the proceeds are received or receivable. A grant received before the recognition criteria are satisfied is recognised as a liability.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was 4 (2018 - 4).

3
Directors' remuneration and dividends
2019
2018
£
£
Remuneration paid to directors
82,792
77,267
4
Debtors
2019
2018
Amounts falling due within one year:
£
£
Corporation tax recoverable
34,516
34,074
Other debtors
53,179
35,094
87,695
69,168
Deferred tax asset
73,182
73,182
160,877
142,350
5
Creditors: amounts falling due within one year
2019
2018
£
£
Trade creditors
5,914
37,474
Taxation and social security
6,494
4,354
Other creditors
122,628
122,172
135,036
164,000

Included within other creditors are debenture loans which are secured on the company's intellectual property.

INOCARDIA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2019
- 5 -
6
Called up share capital
2019
2018
£
£
Ordinary share capital
Issued and fully paid
4,000 Ordinary of 1p each
40
40
6,880 A Ordinary of 1p each
69
69
109
109
7
Events after the reporting date

In December 2019 a new loan agreement was entered into for a principal balance of £125,000. The funds received were used to clear the debenture loans of £63,375 included within other creditors at 30 September 2019.

8
Related party transactions

During the year the company was recharged £18,641 (2018: £22,705) in respect of subcontractor labour provided by a company director.

2019-09-302018-10-01false31 March 2020CCH SoftwareCCH Accounts Production 2019.301No description of principal activityDr J P BillsonDr H MaddockDr R WallisMr P D Noon085734172018-10-012019-09-30085734172019-09-30085734172018-09-3008573417core:CurrentFinancialInstrumentscore:WithinOneYear2019-09-3008573417core:CurrentFinancialInstrumentscore:WithinOneYear2018-09-3008573417core:CurrentFinancialInstruments2019-09-3008573417core:CurrentFinancialInstruments2018-09-3008573417core:ShareCapital2019-09-3008573417core:ShareCapital2018-09-3008573417core:SharePremium2019-09-3008573417core:SharePremium2018-09-3008573417core:RetainedEarningsAccumulatedLosses2019-09-3008573417core:RetainedEarningsAccumulatedLosses2018-09-3008573417core:ShareCapitalOrdinaryShares2019-09-3008573417core:ShareCapitalOrdinaryShares2018-09-3008573417bus:Director12018-10-012019-09-30085734172017-10-012018-09-3008573417core:WithinOneYear2019-09-3008573417core:WithinOneYear2018-09-3008573417bus:PrivateLimitedCompanyLtd2018-10-012019-09-3008573417bus:SmallCompaniesRegimeForAccounts2018-10-012019-09-3008573417bus:FRS1022018-10-012019-09-3008573417bus:AuditExemptWithAccountantsReport2018-10-012019-09-3008573417bus:Director22018-10-012019-09-3008573417bus:Director32018-10-012019-09-3008573417bus:Director42018-10-012019-09-3008573417bus:FullAccounts2018-10-012019-09-30xbrli:purexbrli:sharesiso4217:GBP